Moderna, Inc. (MRNA) shares climbed 13.1% to $258.38 as of November 4, 2026, a sharp gain from the prior close of $228.44. BestStocks flagged the session as a major change for MRNA. Below, we break down what changed for MRNA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
MRNA climbed 13.1% to $258.38
MRNA climbed 13.1% in its latest session, moving from $228.44 to $258.38.
ActivityLow confidence
Rel. volume
0.9×
Below Avg
Vs peers
—
No comparable peers
Market cap
$103.2B
NASDAQ Global Select
Analyst target
$133
-48.6% vs price
Price chart
Oct 5 – Nov 4
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Moderna, Inc. investors
For Moderna, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Strong 13.1% price move; Positive price momentum. Weighing against that: Moderna shares plunged 19.58% to $197.67 after cancer-vaccine trial data leaked ahead of its scheduled presentation at ESMO 2026, per Barron's; Moderna pulled back 6.23% to $190.56 after hitting a 52-week intraday high of $212.22, driven by profit-taking and a sector-wide vaccine stock cooldown following World Health Organization risk updates that dampened speculative momentum. Wall Street's consensus price target sits at $132.70, implying -48.6% downside from $258.38. Over the past 90 days analysts logged 3 upgrades and 3 downgrades. BestStocks rates the overall signal quality low (57/100). With earnings roughly 2 days out, the next report is the most likely near-term test of the move.
MRNA price reaction
MRNA last traded at $258.38, up $29.94 (+13.11%) from the previous close of $228.44. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $187.46 and $258.38, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Moderna, Inc. (MRNA)
The consensus analyst price target on Moderna, Inc. (MRNA) is $132.70, 48.6% below the recent $258.38. Over the past 90 days analysts logged 3 upgrades, 9 maintains, and 3 downgrades. Here is how the bullish and bearish cases on MRNA line up.
▲ The bullish case
+3 analyst upgrades in the past 90 days, most recently Argus Research to Buy (2026-08-28).
+Strong 13.1% price move.
+Positive price momentum.
+Moderna rallied 6.10% to $201.60 on index inclusion momentum and pipeline optimism.
▼ The bearish case
−The consensus analyst price target of $132.70 sits 48.6% below the recent $258.38, so the average target sees limited room to run.
−The most bearish analyst target is $25.00 (-90.3%).
−3 analyst downgrades in the past 90 days, most recently William Blair to Market Perform (2026-10-27).
−Moderna shares plunged 19.58% to $197.67 after cancer-vaccine trial data leaked ahead of its scheduled presentation at ESMO 2026, per Barron's.
−Moderna pulled back 6.23% to $190.56 after hitting a 52-week intraday high of $212.22, driven by profit-taking and a sector-wide vaccine stock cooldown following World Health Organization risk updates that dampened speculative momentum.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 4, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Analyst expectations
Consensus target: $133-48.6%
↑ 3 upgrades= 9 maintains↓ 3 downgrades
William Blair downgraded to Market Perform · 2026-10-27
Moderna shares plunged 19.58% to $197.67 after cancer-vaccine trial data leaked ahead of its scheduled presentation at ESMO 2026, per Barron's. The company and partner Merck had announced positive Phase 3 results for intismeran autogene plus KEYTRUDA in melanoma, but premature circulation of the data sparked the sharp sell-off. Volume surged to 42.8M shares—2.48x the historical average for this time of day—and a securities fraud investigation was announced the same day.
Moderna rose 4.58% to $237.28, extending recent momentum. The evidence includes a prior report (Oct 30, 2025) of potential buyout talks via STAT News that drove a 12% surge, and a Barclays analyst upgrade (Aug 25, 2026) that raised the price target to $125 from $48 while maintaining Equal Weight. Current intraday volume of 8.1M shares is 0.91x historical average—normal for this point in the session.
Moderna shares fell 10.49% to $211.69 on October 16, 2026, driven by pre-event profit-taking and derisking ahead of a Phase 3 data presentation later in the month for its personalized melanoma vaccine partnership with Merck, according to investing.com. The decline follows a multi-week rally that pushed the stock near 52-week highs, prompting investors to lock in gains; sentiment was also pressured by insider selling (Form 144 filings from executives including Stephen Hoge) and news that rival Summit Therapeutics hired two former Moderna cancer vaccine scientists.
Moderna surged +11.51% to $219.68, driven by two catalysts: an exclusive report (New York Times, per web sources) detailing a major national public-private partnership to accelerate mRNA cancer vaccine development, and the company's official reinclusion in the Nasdaq-100 Index effective today. Volume traded 2.15x the historical average for this time of day, signaling broad institutional participation.
Moderna pulled back 6.23% to $190.56 after hitting a 52-week intraday high of $212.22, driven by profit-taking and a sector-wide vaccine stock cooldown following World Health Organization risk updates that dampened speculative momentum. The retreat also reflects investor caution around stretched valuations and elevated expectations for the oncology pipeline ahead of clinical data releases, as cited by recent Wall Street "Sell" ratings.
Moderna rallied 6.10% to $201.60 on index inclusion momentum and pipeline optimism. The stock is set to join the Nasdaq-100 on October 9, 2026, triggering accumulation by passive funds (per web search synthesis), while investor sentiment remains buoyed by strong Phase 3 results for its personalized melanoma vaccine co-developed with Merck. Volume of 10.3M shares at 230 minutes into the session runs 1.20x normal for this time of day.
Citigroup downgraded Moderna from Neutral to Sell, citing an overextended rally following the melanoma vaccine trial win and arguing current valuations price in unrealistic cross-tumor sales projections (per Seeking Alpha). The stock fell 7.03% to $189.15. Volume was 1.95x expected for this point in the session, and the decline also reflects reported patent litigation headwinds — a federal court denied Moderna's motion to dismiss infringement claims from Bayer's Monsanto unit over foundational mRNA technology.
In-depth MRNA event analyses
Permanent, dated analyses of MRNA's most significant sessions.
MRNA climbed 13.1% to $258.38. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MRNA stock rise?
MRNA gained 13.11% ($29.94) versus the prior close of $228.44, last trading at $258.38 on 0.9× average volume.
When is Moderna, Inc.'s next earnings date?
MRNA's next earnings report is estimated for 2026-11-06 — about 2 days away.
What is the analyst price target for MRNA?
The consensus analyst price target for MRNA is $132.70, about 48.6% below the current $258.38. Over the past 90 days, analysts recorded 3 upgrades, 9 maintains, and 3 downgrades.
How BestStocks tracks MRNA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRNA-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MRNA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 4, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
